Claim: Lily and Novo Nordisk are the two companies that make GLP-1 medications, and they are involved in lobbying against compounded versions of these drugs.
Verdict: Correct (90% confidence)
Explanation: According to the STOP Obesity Alliance, Novo Nordisk and Eli Lilly have requested the FDA to list semaglutide and tirzepatide as drugs that are difficult to compound, which supports the claim of their involvement in lobbying against compounded versions (source 3). Health Journalism also reports that Novo Nordisk and Eli Lilly have been actively campaigning against compounded versions of their GLP-1 drugs, further supporting the claim (source 5). Novo Nordisk's own website confirms their stance a...